DNCURE
Dynamic signalling networks in Diabetic Nephropathy (DN) – New avenues to a personalized therapy.-
| Coordinatore | UNIVERSITAETSKLINIKUM FREIBURG
Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie. |
| Nazionalità Coordinatore | Germany [DE] |
| Totale costo | 1˙999˙920 € |
| EC contributo | 1˙999˙920 € |
| Programma | FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | ERC-2013-CoG |
| Funding Scheme | ERC-CG |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-06-01 - 2019-05-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
UNIVERSITAETSKLINIKUM FREIBURG
Organization address
address: HUGSTETTER STRASSE 49 contact info |
DE (FREIBURG) | hostInstitution | 1˙999˙920.00 |
| 2 |
UNIVERSITAETSKLINIKUM FREIBURG
Organization address
address: HUGSTETTER STRASSE 49 contact info |
DE (FREIBURG) | hostInstitution | 1˙999˙920.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Dynamic signalling networks in Diabetic Nephropathy (DN) – New avenues to a personalized therapy.- We have developed an exquisite experimental platform that facilitates the systematic unravelling of the signalling networks leading to (1) the initiation, (2) the progression and (3) the potential regeneration of podocytes in DN, paving the way to novel therapeutic strategies: (1) DN initiation: Identification of signalling cascades leading to microalbuminuria: Molecular By combining transgenic Drosophila lines carrying secreted fluorescent proteins to monitor the barrier function in vivo with a genome-wide siRNA screen we will establish a unique system to directly identify gene networks contributing to microalbuminuria. (2a) DN progression: Molecular fingerprinting of podocyte degeneration: Based on a transgenic fluorescent mouse model, we have pioneered a highly efficient podocyte purification method from type1 and type 2 diabetic mice allowing us to develop a precise molecular genetic, quantitative proteomic and micro RNA fingerprint from freshly isolated podocytes from diabetic and non-diabetic mice. (2b) DN progression: We established a proteomic approach to measure site-specific phosphorylation dynamics in primary podocyte cultures originating from transgenic mice that are TORC1 deficient, TORC2 deficient or TORC1 hyperactive (TSC1 KO) solely in the podocytes. (3) Potential role of podocyte regeneration in DN: Finally, to target mechanisms that could potentially reverse the disease process (by repopulating lost podocytes), we invented a strategy to quantitatively monitor podocyte turnover from different stem cell niches allowing us to precisely assess and potentially manipulating the capacity of podocyte regeneration in DN.'